Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 3/20 | 0.46 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863972 | 1.00 | GRM5 (0.55) | GRM5MKNK1MKNK2SIGMAR1HPGD | |
| SCHEMBL10138889 | 0.94 | HRH3 (0.59) | GRM5MKNK1MKNK2SIGMAR1HPGD | |
| SCHEMBL20687922 | 0.85 | GRM5 (0.67) | GRM5HPGDALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5909240 | 0.85 | GRM5 (0.71) | GRM5HPGDALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL8253628 | 0.84 | SIGMAR1 (0.57) | MKNK1MKNK2SIGMAR1HPGDHRH3 | |
| SCHEMBL5909310 | 0.84 | GRM5 (0.73) | GRM5HPGDALDH1A1KDM4E | |
| SCHEMBL601820 | 0.84 | ALDH1A1 (0.53) | GRM5MKNK1MKNK2HPGDHRH3 | |
| SCHEMBL13850295 | 0.83 | SIGMAR1 (0.56) | MKNK1MKNK2SIGMAR1HPGDHRH3 | |
| SCHEMBL5908983 | 0.83 | GRM5 (0.58) | GRM5MKNK1MKNK2HPGDHRH3 | |
| SCHEMBL5909238 | 0.81 | HPGD (0.64) | GRM5HPGDGABRA5ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| WO-2021003050-A2 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20180022704-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-9809547-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-07 | — | — | US | disclosed |
| US-20170057919-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-9518021-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-13 | — | — | US | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
| US-20140343279-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-20 | — | — | US | disclosed |
| US-8748596-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-02 | — | — | US | disclosed |
| CN-102099337-A | Piperazine derivatives useful as CAV2.2 calcium channel modulators | CONVERGENCE PHARMACEUTICALS | 2011-06-15 | — | — | CN | disclosed |
| EP-2300432-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | GRM5 397/4885MKNK1 2308/4885MKNK2 1019/4885 |
| US-20170057919-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | GRM5 41/4885MKNK1 1775/4885MKNK2 2028/4885 |
| US-20180022704-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | GRM5 41/4885MKNK1 1775/4885MKNK2 2028/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | GRM5 3425/4885MKNK1 3522/4885MKNK2 2857/4885 |
| US-20140343279-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | GRM5 41/4885MKNK1 1775/4885MKNK2 2028/4885 |
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | GRM5 41/4885MKNK1 1775/4885MKNK2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.